Welcome to our dedicated page for United Health Pr news (Ticker: UEEC), a resource for investors and traders seeking the latest updates and insights on United Health Pr stock.
United Health Products, Inc. (UEEC) is a medical device company that develops, manufactures and markets hemostatic gauze products based on a patented Neutralized Regenerated Cellulose technology. Its news flow is heavily focused on regulatory milestones, clinical data and financing developments related to its CelluSTAT (formerly HemoStyp) hemostatic gauze.
On this page, readers can follow company press releases that detail United Health Products’ FDA Premarket Approval (PMA) application process, including submissions via the FDA’s eSTAR platform, responses to FDA deficiencies letters and interactions with regulators such as videoconferences and Submission Issue Requests. Updates also cover required testing on manufacturing consistency, packaging integrity, radiation sterilization, product stability and bioburden levels for its Class III medical device candidate.
News items highlight clinical trial results for CelluSTAT, including pivotal study outcomes on time to hemostasis versus standard of care, and describe the design and objectives of planned supplemental clinical studies in specific surgical settings. The company’s communications also address its efforts to secure external funding to support clinical work and regulatory tasks, as well as capital markets activities such as securities purchase agreements, convertible notes, purchase warrants and any market purchase arrangements.
Investors and observers can use this news feed to track how United Health Products advances its Neutralized Regenerated Cellulose hemostatic products in dental, veterinary, emergency medicine and potential human surgical markets, and to monitor statements about board composition, potential uplisting plans and investor relations initiatives. Bookmark this page for an organized view of UEEC press releases and related company announcements.
United Health Products, Inc. (OTC: UEEC) has announced the international publication of its patent application for a hydrocolloid format of its hemostatic agent, HemoStyp, under the Patent Cooperation Treaty. This publication allows UHP up to one year to file specific patents in desired countries as it progresses with gel-related R&D. CEO Brian Thom highlighted the potential to expand HemoStyp's market beyond gauze formats, targeting surgical fields like spinal and vascular procedures. The company emphasizes the significance of establishing a global IP portfolio for maximizing technology value.
United Health Products, Inc. (OTC: UEEC) has appointed John Phillips as Vice President of Marketing & Commercial Strategy, effective December 15, 2020. With over 30 years of experience in product commercialization, he will lead UHP’s global commercial strategies for its patented hemostatic agent, HemoStyp. UHP anticipates receiving its FDA PMA, transitioning to commercialization, and enhancing revenue across priority markets. The company aims to leverage Phillips' industry relationships and expertise to improve patient outcomes and reduce care costs.